As part of a systematic elucidation of the pharmacology of prostaglandin's (PG) effects on intraocular pressure in the monkey, the prototypical selective prostanoid EP 4 receptor agonist (3,7-dithia PGE 1 ) was examined. It was found to be highly efficacious in nonhuman primates, and its mechanism of ocular hypotensive activity was investigated. METHODS. Intraocular pressure (IOP) was measured by pneumatonometry in conscious monkeys restrained in custom-designed chairs. All other animal experiments were performed in animals sedated with ketamine or anesthetized with ketamine/ diazepam and given drug or vehicle for various lengths of time. Aqueous flow was determined by fluorophotometry. Total outflow facility was measured by the two-level, constant-pressure method and by 2-minute tonography in both normotensive and hypertensive monkey eyes. Uveoscleral outflow was measured by perfusing the anterior chamber with FITC-labeled dextran for 30 minutes at a fixed IOP of approximately 15 mm Hg. Isometric responses to drugs were measured in longitudinal and radial preparations of monkey and human isolated ciliary smooth muscle specimens. RESULTS. The selective EP 4 receptor agonist 3,7-dithia PGE 1 and an isopropyl ester prodrug thereof reduced IOP in monkeys. A single dose of 3,7-dithia PGE 1 isopropyl ester, at a 0.01% or 0.1% dose, decreased IOP in the glaucomatous monkey in the range of 40% to 50%. Studies on total outflow facility by the two-level, constant-pressure perfusion method and tonography indicated that EP 4 receptor stimulation facilitated aqueous humor outflow facility. No effect on aqueous flow was apparent. In contrast to all PGs and prostamides studied to date, 3,7-dithia PGE 1 exerted no effect on uveoscleral outflow measured directly. Moreover, it did not relax longitudinal or radial preparations of isolated human or monkey ciliary muscles. CONCLUSIONS. The EP 4 receptor agonist 3,7-dithia PGE 1 is a highly efficacious IOP-lowering drug in monkeys. It has no effect on uveoscleral outflow but does increase total outflow facility, which accounts for a substantial proportion of the ocular hypotensive activity. (Invest Ophthalmol Vis Sci. 2009; 50:3320 -3328) DOI:10.1167/iovs.08-3031 N atural prostaglandins are potent and efficacious ocular hypotensive agents. They are now known to exert their effects by interacting with at least nine distinct target receptors, but detailed understanding of their role in aqueous humor dynamics is an ongoing endeavor. Over the past few years, selective agonists and antagonists for each of the prostanoid receptors have emerged. These represent invaluable tool drugs for completing a detailed investigation of the ocular pharmacology of PGs on a functional basis. To date, selective agonists for DP, EP 2 , and FP receptors all have been shown to reduce intraocular pressure (IOP) in nonhuman primates.
N atural prostaglandins are potent and efficacious ocular hypotensive agents. They are now known to exert their effects by interacting with at least nine distinct target receptors, but detailed understanding of their role in aqueous humor dynamics is an ongoing endeavor. Over the past few years, selective agonists and antagonists for each of the prostanoid receptors have emerged. These represent invaluable tool drugs for completing a detailed investigation of the ocular pharmacology of PGs on a functional basis. To date, selective agonists for DP, EP 2 , and FP receptors all have been shown to reduce intraocular pressure (IOP) in nonhuman primates. [1] [2] [3] [4] [5] [6] [7] Of interest, the underlying mechanisms involved in ocular hypotension produced by DP, EP 2 , and FP receptor stimulation in nonhuman primates appear to exclusively involve increased uveoscleral outflow. 6 -11 This finding may be regarded as unexpected, as these receptors are not only discrete entities but do not couple with the same signal-transduction mechanisms. As part of a systematic attempt to completely characterize the pharmacology of PG-induced ocular hypotension, we investigated the effects of the first selective EP 4 receptor agonist to be described, 3,7-dithia PGE 1 . 12 It is not surprising that selective EP 4 agonists only recently have been described, because the EP 4 receptor was the last prostaglandin E 2 (PGE 2 )-sensitive receptor to be proposed as part of the original pharmacologic classification for prostanoid receptors. 13 The mouse and human EP 4 receptors were cloned contemporaneously 14, 15 but were misnamed EP 2 until the authentic EP 2 receptor sequence was reported. 16 Structurally, the EP 4 receptor is characterized by a long cytoplasmic terminus that is claimed to be involved in agonist-induced receptor desensitization and internalization. [17] [18] [19] [20] The EP 4 receptor is widely distributed. [13] [14] [15] [21] [22] [23] EP 4 receptors have been reported to be widely represented in human ocular tissues, according to extensive immunolocalization studies 24 and were present in every tissue and cell, with the following exceptions: iris epithelium, ciliary process blood vessels, retinal blood vessels, and Müller cells. 24 Studies involving reverse transcription-polymerase chain reaction (RT-PCR) 24 -27 and function provide corroborative evidence for the immunolocalization results. The expression of EP 4 receptors in trabecular meshwork cells, endothelial cells lining Schlemm's canal, collector channels, aqueous veins, ciliary epithelium, ciliary muscle, and ciliary body stromal cells 24, 26, 27 is particularly relevant to aqueous humor dynamics and drugs that reduce IOP.
Given the abundant message for prostanoid EP 4 receptors in the trabecular meshwork, 24 this tissue could be regarded as a likely target for EP 4 receptor-mediated ocular hypotensive activity. Increased trabecular outflow facility is an attractive mechanism of action for an antiglaucoma medication, since such an agent would treat the disease closer to its origin. 28 -31 Other potential mechanisms also are possible, given the wide ocular distribution of EP 4 receptors. 24 With this background information, it was considered worthwhile to study the ocular hypotensive activity and related mechanisms by using the first selective EP 4 receptor agonist 3,7-dithia PGE 1 .
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METHODS
The experiments adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the animal care and use committees of each institution.
Intraocular Pressure
IOP studies were performed in conscious female cynomolgus monkeys (Macaca fascicularis) weighing 2 to 4 kg. All treatments were masked for the experimenters. Cynomolgus monkeys trained to accept pneumatonometry were restrained in chairs custom designed for the procedure. Ocular normotensive monkeys and monkeys rendered unilaterally ocular hypertensive by circumferential argon laser treatment of the trabecular meshwork were used. IOP was measured by means of an applanation pneumatonometer. One minute before pneumatonometry, 25 L of proparacaine was applied to minimize ocular discomfort during the measurement. Determination of the effects of drugs on IOP involved administration of 25 L of drug solution (3,7-dithia PGE 1 and its isopropyl ester, 0.01%) to one eye (lasered eye in the case of glaucomatous monkeys) and an equal volume of vehicle (sterile saline with 1% polysorbate 80, 5 mM Tris-HCl) to the contralateral, normotensive eye as a control. IOP was measured at 1 hour before drug administration, just before drug administration, and at 2, 4, and 6 hours thereafter.
Aqueous Humor Dynamics
Cynomolgus monkeys of both sexes, approximately 2 to 8 years of age and weighing between 2.2 and 4 kg, were used. For aqueous flow studies, ocular normotensive monkeys were treated bilaterally with a single dose of study drug on one day and vehicle on a separate day. For uveoscleral outflow studies, ocular normotensive monkeys were treated once daily for 5 days with 25 L of drug solution administered to one eye and 25 L of vehicle administered to the contralateral eye. For total outflow facility studies, ocular normotensive monkeys were given a single morning dose of study drug in one eye and vehicle in the contralateral eye. For tonography, both eyes were treated once a day for 4 days. Between 4 and 6 hours after drug administration, the animals were anesthetized and measurements were made as described in the next section.
Total Outflow Facility: Two-Level, Constant-Pressure Method. Monkeys were injected intramuscularly with a mixture of ketamine (100 mg/mL) 0.15 mL/kg body weight and diazepam (5 mg/mL) 0.3 mL/kg body weight, to provide a deep level of anesthesia and an absence of eye movements. Supplemental doses of ketamine (0.075 mL/kg body weight) were given at 30-minute intervals during the course of the experiment, and additional doses of diazepam (0.15 mL/kg body weight) were given at 60-minute intervals. Vital signs (i.e., heart rate and body temperature) were continuously monitored. After a stable and deep level of anesthesia had been achieved, IOP was determined with a calibrated pressure transducer system. Total outflow facility was then determined by the two-level, constant-pressure method described by Bárány. 32 Briefly, the anterior chamber was connected through a 25-gauge stainless-steel needle to a fluid reservoir containing a modified mock aqueous humor solution. 33 In this system, the actual IOP is dependent on the hydrostatic pressure of the solution in the reservoir and can be adjusted as necessary. The pressure in the eye was changed at 10-minute intervals between two different pressure levels approximately 2.5 (p 1 ) and 10 mm Hg (p 2 ) above the real IOP level, which, in this context, describes the IOP that would be present in the eye if the pressure were not artificially maintained by means of a reservoir. Keeping the artificial pressure above real IOP ensures the flow of fluid from the reservoir. For each 10-minute measurement period at p 1 or p 2 , the flow rate of fluid from the reservoir was determined as F 1 or F 2 , respectively. Flow rates were calculated as F ϭ ⌬W/t with ⌬W representing the weight difference of the reservoir between the beginning and end of the measurement period and t representing the duration of the period. Total outflow facility C could then be calculated with the equation
Total outflow facility in each eye was averaged over five measurement periods. The outflow facility studies were performed twice in the same animals approximately 4 months apart, at baseline, and after treatment.
Tonography. Eight female cynomolgus monkeys with laser-induced glaucoma in one eye were used in this crossover experiment. Baseline IOPs and administration of drug or vehicle were performed in conscious trained animals. Doses of 25 L of either drug or vehicle were administered once daily at 9:00 AM for 4 days. Four hours after the last dose, the animals were sedated with ketamine and a 2-minute tonography measurement was performed in each eye with the tonography mode of a pneumatonometer (Reichert, Depew, NY). Data were stored on a computer (PowerLab software; ADInstruments, Colorado Springs, CO). Calculations were performed in commercial software (Excel; Microsoft, Redmond, WA). One week later, the animals were given the alternate solution, and the tonography was repeated.
Uveoscleral Outflow. To determine the effect on uveoscleral outflow, we used the anterior chamber perfusion method originally developed by Bill 34 and subsequently modified by Toris et al., 35 using a fluorescein-tagged tracer. This method employs the principle of determining the amount of tracer in ocular tissues after perfusing the anterior chamber with a solution containing a high-molecular-weight tracer. Each eye was cannulated with three 25-gauge needles, two of which were connected to 5-mL gas-tight syringes mounted in a reciprocal syringe pump (Harvard Apparatus, Holliston, MA), the third was connected to an open fluid reservoir with an in-line pressure transducer, to record IOP. A reciprocal pump (Harvard Apparatus) allowed perfusion of the anterior chamber at a predetermined flow rate without affecting IOP. Both eyes were perfused for 30 minutes with a mock aqueous humor solution 33 containing 0.7% (1 ϫ 10 Ϫ4 M) FITC-dextran 70,000 as a tracer. To provide for a quick exchange of the anterior chamber content with the tracer, the eyes were perfused for the first 5 minutes at a rate of 0.2 mL/min and then during the remaining 25 minutes at a rate of 0.05 mL/min. The perfusates from those two perfusion periods were collected separately as primary and secondary perfusates, respectively. The IOP in both eyes was clamped during the anterior chamber perfusion at approximately 15 mm Hg, via the open reservoir. At the conclusion of the 30-minute perfusion period the animal was euthanatized with an overdose of pentobarbital sodium (2 mL; Eutha-6 CII; Wester Medical, Santa Ana, CA). Both eyes were then perfused for approximately 10 minutes with mock aqueous humor solution, without tracer, to wash the tracer out of the anterior chamber. The eyes were then enucleated and immediately dissected into anterior sclera, posterior sclera (posterior to ora serrata), extraocular tissues, ciliary body, choroid, and retina, and vitreous humor and other fluids including wash fluid were collected. The cornea, lens, and iris were excluded from the measurements because these tissues are not thought to contribute to uveoscleral outflow. Each tissue was homogenized in Dulbecco's phosphate-buffered saline (D-PBS) and centrifuged. The FITC-dextran concentration in the supernatant was determined with a spectrometer (LS-50B; PerkinElmer, Wellesley, MA) with excitation and emission wavelengths of 493 and 515 nm, respectively, and 5.0 nm excitation and emission slits. Total uveoscleral outflow (F u ) was calculated with the equation Aqueous Flow. Female cynomolgus monkeys between the ages of 3 and 8 years were included in the study. Sedation was produced by ketamine hydrochloride, 1 to 5 mg/kg, administered by intramuscular or intravenous injection to achieve pharmacologic restraint. Animals were seated for tonometry and pachymetry measurements and prone for fluorophotometry measurements. Corneal thickness and anterior chamber depth were measured by ultrasound pachymetry (Sonomed, Inc., Lake Success, NY) and corneal diameter was measured with a ruler. Cornea and anterior chamber volumes were calculated from these values. 36 Next, fluorescein (10% in 2% agar gel) was applied to the cornea using iontophoresis for various lengths of time. One 25-L drop of vehicle was applied to each eye at approximately 9 AM. The fluorescence of the cornea and anterior chamber were measured with a scanning ocular fluorophotometer (Fluorotron; OcuMetrics, Palo Alto, CA). Scans were taken in duplicate at 60-minute intervals for four sets. These data were used to determine aqueous flow (F a ). 36 F a measurements were repeated 3 days later, 4 hours after a topical 25-L drop of drug.
Statistical Analyses
Comparisons were made by Student's two-tailed t-test for paired observations. Differences were assumed to be statistically significant at P Ͻ 0.05.
Isolated Ciliary Muscle
Ciliary smooth muscle specimens were surgically excised from enucleated human eyes (obtained from the National Disease Research Interchange, Philadelphia, PA), in accordance with the guidelines of the Declaration of Helsinki for research involving human tissue, and monkey eyes and were set up as either longitudinal or radial (circular) preparations in 15- 
Human Recombinant Receptor Studies
The use of chimeric G protein cDNAs allowed responses to G s -and G i -coupled prostanoid receptors to be measured as a Ca 2ϩ signal, as previously described. 37 Prostanoid DP, EP 2 , and EP 4 receptor cDNAs were cotransfected with chimeric G qs cDNA containing a hemagglutinin (HA) epitope. The prostanoid EP 3 receptor was cotransfected into HEK-293 EBNA cells, using pCEP 4 as a vector, with chimeric G qi -HA. G qs and G qi chimeric cDNAs (Molecular Devices, Sunnyvale, CA) were cloned into a pCEP 4 vector and also selected by using a hygromycin B selection marker. Transfection into HEK-293 EBNA cells was then performed by a commercial method (FuGENE 6; Roche, Indianapolis, IN). Because G qs and G qi contained an HA epitope, protein expression was detected by Western blot analysis with anti-mouse HA monoclonal antibody and horseradish peroxidase (HRP)-conjugated secondary antibody. For the human recombinant EP 1 , FP, IP, and TP receptors, stable transfectants were obtained as previously described. 37 Briefly, pCEP 4 was used as the expression vector, and transfection into HEK-293-EBNA cells was performed (FuGENE 6; Roche). Stable transfectants were again selected according to hygromycin resistance. 
RESULTS
The Ca 2ϩ signaling studies, using stable human prostanoid receptor stable transfectants, confirmed the original radioligand binding studies that reported 3,7-dithia PGE 1 as a selective EP 4 agonist. 12 It was Ͼ100-fold selective for EP 4 than for EP 3 and the relative selectivity at other receptors was 1000-fold or more (Table 1) .
The effects of 3,7-dithia PGE 1 on the IOP of laser-induced, ocular hypertensive monkeys are depicted graphically in Figure 1. A 0.1% dose of 3,7-dithia PGE 1 produced a decrease in IOP of more than 10 mm Hg (Fig. 1a) . Vehicle produced no significant IOP effect (Fig. 1b) . The ocular hypotensive efficacy in monkeys was improved by esterification of the carboxylic acid of 3,7-dithia PGE 1 . Thus, the isopropyl ester derivative, at both 0.01% and 0.1% doses, caused more than a 15-mm Hg (40%-50%) decrease in IOP (Fig. 2) . The IOP of the ocular hypertensive eye was essentially reduced to that of the nonlasered, vehicle-treated control eye. No effect on pupil diameter was noted.
The effects of 3,7-dithia PGE 1 isopropyl ester on the IOP of normotensive monkey eyes is shown in Figure 3 . Both a 0.01% (Fig. 3a) and 0.1% (Fig. 3b) dose produced a decrease in IOP of 2 to 3 mm Hg.
The effects of 0.01% 3,7-dithia PGE 1 isopropyl ester on total outflow facility (l/min/mm Hg) are summarized in Table 2 . A 35% increase in pressure-dependent outflow was achieved at 4 to 6 hours after treatment. P Ͻ 0.05 was obtained when the ratio of treated over control eye outflow facility (1.34 Ϯ 0.15) was compared against the difference between eyes before treatment (ratio, 1.04 Ϯ 0.05).
Tonography studies revealed that outflow facility was significantly less in ocular hypertensive (OHT) eyes than in ocular normotensive (ONT) eyes treated with vehicle (P ϭ 0.003), a result to be expected in a laser-induced glaucoma model. When drug was administered, outflow facility was not different between the two eyes, which suggests that outflow facility in the lasered eyes recovered to some extent. The EP 4 agonist significantly (P ϭ 0.04) increased outflow facility in OHT but not ONT eyes (Table 3) . The EP 4 agonist produced no significant difference in uveoscleral outflow compared with that in vehicle-treated control eyes (Table 4 ) and did not alter aqueous flow in normotensive eyes compared with that at baseline ( Table 5 ).
The effects of graded doses of 3,7-dithia PGE 1 , butaprost, and PGE 2 relative to a single dose of atropine on longitudinal and radial preparations of the human ciliary muscle are depicted in Figure 4 . 3,7-dithia PGE 1 produced virtually no relaxation of the precontracted longitudinal (Fig. 4a) or radial (Fig.  4b ) human ciliary muscle, even when a 10 Ϫ5 -M concentration was reached, which is far in excess of that necessary to fully activate EP 4 receptors. Butaprost-free acid and PGE 2 were more active (Figs. 4c-f ) and the magnitude of the relaxant responses to PGE 2 was comparable to those previously reported for human ciliary muscle for relaxation measured in milligrams. 38 In marked contrast, a single 10 Ϫ7 concentration of atropine reversed carbachol-induced contraction of both longitudinal and radial ciliary muscle preparations (see Fig. 6 ). Given the modest relaxant effects of PGE 2 compared with that of atropine, it was considered preferable to measure relaxant responses as a percentage of atropine response. Similar results were obtained in the isolated monkey ciliary muscle (Fig. 5) , although fewer tissues were examined, as monkey eyes rarely became available for study. The EP 4 agonist 3,7-dithia PGE 1 produced no meaningful relaxation of longitudinal (Fig 5a) or radial (Fig. 5b) monkey ciliary muscle preparations. Butaprostfree acid had little effect on longitudinal monkey ciliary smooth muscle (Fig. 5c ) but appeared to produce a greater effect in radial preparations (Fig. 5d) . PGE 2 also produced a greater effect in radial ciliary muscle preparations (Figs. 5e, 5f ). Atropine produced a pronounced relaxation of ciliary muscle specimens precontracted with carbachol, thereby again indicating that the ciliary muscle preparations were viable.
Actual traces of monkey longitudinal (Fig. 6a) , human longitudinal (Fig. 6b), monkey radial (Fig. 6c) , and human radial (Fig. 6d) experiments are provided in Figure 6 . It can be seen that 3,7-dithia PGE 1 produced no meaningful relaxant effect, whereas atropine substantially reversed carbachol-induced contraction in all cases.
DISCUSSION
The selective prostanoid EP 4 receptor agonist, 3,7-dithia PGE 1 and its isopropyl ester were found to possess clear ocular hypotensive activity in normal and ocular hypertensive monkeys. In laser-induced ocular hypertensive monkeys, a single 0.01% or 0.1% dose of 3,7-dithia PGE 1 isopropyl ester reduced IOP to the level of that measured in the untreated, ocular normotensive control eyes. Simply stated, 3,7-dithia PGE 1 isopropyl ester normalized elevated IOP. The IOP results obtained with 3,7-dithia PGE 1 and its isopropyl ester were pursued further by studying the underlying aqueous humor dynamics.
The effects of 3,7-dithia PGE 1 isopropyl ester on IOP in normal and glaucomatous monkeys remained very evident at the termination of the studies. This ocular hypotensive activity profile could be viewed as consistent with long-term effects on aqueous humor dynamics-perhaps the ultrastructural changes that provide the morphologic basis of increased uveoscleral outflow. 6 Contrary to expectations and unlike the prostanoid DP, 7 the FP 8,10,11 and EP 2 6,8 agonists, and a prostamide, 8 the selective EP 4 agonist 3,7-dithia PGE 1 exhibited no significant effect on uveoscleral outflow.
In addition to direct measurement of uveoscleral outflow, EP 4 receptor-mediated regulation of IOP and uveoscleral outflow was investigated indirectly by studying its effects on ciliary muscle tone. It has often been suggested that relaxation or inhibition of ciliary muscle contraction may result in increased uveoscleral outflow, thus reducing IOP. 39 Studies in nonhuman primates have directly demonstrated that agents that relax ciliary smooth muscle may result in an increase in uveoscleral outflow. 39, 40 To date PGs, atropine, 39 -44 and inhibitors of Rho-associated coiled coil-forming protein kinase (ROCK) have been proposed to increase uveoscleral outflow with the potential for lowering IOP. We therefore elected to study the effects of 3,7-dithia PGE 1 , PGE 2 , butaprost, and atropine on the tone of carbachol precontracted human and monkey ciliary muscle. The longitudinal preparation has been suggested to more closely model the outflow route via the ciliary muscle, 43 ,44 but we also examined specimens prepared in the radial orientation. Although there are ultrastructural, histo- Outflow was measured by an intracameral tracer method in ocular normotensive cynomolgus monkeys. Data are the mean uveoscleral outflow (L/min) Ϯ SEM; n ϭ 6. Outflow was measured by fluorophotometry in ocular normotensive monkey eyes. No significant drug effects were obtained, according to Students' two-tailed, paired t-test (P ϭ 0.9). Data are the mean aqueous humor flow (L/min) Ϯ SEM. n ϭ 5-8. [43] [44] [45] responses to carbachol, PGE 2 , butaprost, and atropine were similar. Atropine caused a pronounced relaxation of both circular and longitudinal ciliary smooth muscle, which is consistent with its reported effects on uveoscleral outflow. 39, 40 In contrast, 3,7-dithia PGE 1 produced very little ciliary smooth muscle relaxation, less than that reported for PGF 2␣ relaxation of rhesus monkey ciliary muscle. 44 This virtual lack of relaxant effect apparent for 3,7-dithia PGE 1 further substantiates the finding that it does not alter uveoscleral outflow.
Although the selective EP 4 agonist 3,7-dithia PGE 1 exhibited no significant effect on uveoscleral outflow, it did produce a significant 35% increase in total outflow facility, as measured by the two-level, constant-pressure method. This increase in outflow facility also was found in ocular hypertensive eyes according to tonographic studies, but not in normotensive eyes. This difference may reflect differences in the methodology and associated sensitivity. Taken together, they suggest that 3,7-dithia PGE 1 isopropyl ester lowers IOP by increasing trabecular outflow facility. Absence of effects on uveoscleral outflow and aqueous humor formation indirectly support this contention. These results set EP 4 agonist effects apart from those of prostanoid DP, EP 2 , and FP agonists and prostamides, where increased uveoscleral outflow is the predominant mechanism of action. The EP 4 agonist increased total outflow facility, presumed largely to be trabecular outflow facility. A marked decrease in episcleral venous pressure could contribute to the ocular hypotensive effects of 3,7-dithia PGE 1 . If episcleral venous dilatation were to occur, it would be a contributory factor in ocular surface hyperemia. However, no pronounced ocular surface hyperemic response to 3,7-dithia PGE 1 isopropyl ester was noted that was contemporaneous with the IOP readings in conscious monkeys.
Considering the effects on aqueous humor secretion, prostaglandins tend to increase aqueous humor inflow. 46 3,7-dithia Prostanoid EP 4 Receptor-Mediated IOP Effects 3325 PGE 1 did not alter aqueous humor flow, measured fluorophotometrically, and it appears that decreased aqueous humor production is not a contributory factor to its effect on IOP. We were interested in knowing whether ciliary muscle relaxation may represent a first phase of increased uveoscleral outflow, followed by a second phase that involves remodeling and the creation of new outflow channels. Within the scope of these present studies, we examined the effects of both 3,7-dithia PGE 1 and the EP 2 agonist butaprost on ciliary muscle tone. It is already known that EP 2 agonists lower IOP by increasing uveoscleral outflow exclusively. 6 Butaprost, like 3,7-dithia PGE 1 , produces a rapid reduction in IOP that almost certainly precedes initiation of ciliary muscle remodeling to form new and widened outflow channels. The results of this present study suggest that ciliary muscle relaxation had minimal influence on IOP. 3,7-dithia PGE 1 caused no meaningful relaxation of ciliary smooth muscle. Butaprost did relax longitudinal and radial ciliary smooth muscle slightly more than 3,7-dithia PGE 1 , but much less than atropine. These results may even be taken to suggest that butaprost causes a rapid-onset ocular hypotensive response that is not readily explained by current aqueous humor dynamics concepts.
In summary, the prototypical EP 4 receptor-selective agonist 3,7-dithia PGE 1 was found to be very efficacious in lowering IOP in cynomolgus monkeys. Unlike previously described receptor selective prostanoid analogues (FP, EP 2 , DP) and the prostamide bimatoprost, 7-11 3,7-dithia PGE 1 did not appear to exert a meaningful effect on uveoscleral outflow but increased trabecular outflow facility. Considering second-messenger pathways beyond G protein coupling and gene regulation, regulated by EP 2 and EP 4 receptors, it is not entirely unexpected that EP 4 agonist effects on aqueous humor dynamics exhibit a separate identity. For example, T-cell factor (Tcf) signaling also involves phosphatidyl inositol 3-kinase (PI3K) in the case of EP 4 receptors. 47 Further, EP 4 receptors, but not EP 2 receptors, can activate extracellular signal-regulated kinase (ERK)-1 and -2 via a PI3K pathway, to induce early growth response factor (ERG)-1. 48 The EP 4 receptor may therefore (f) radial Comparison of the effects of graded doses of 3,7-dithia PGE 1 , butaprost, PGE 2 , and 10 Ϫ7 M atropine on precontracted longitudinal and radial monkey ciliary smooth muscle preparations. Mean Ϯ SEM; 3,7-dithia PGE 1 longitudinal (a) n ϭ 3, radial (b) n ϭ 3; butaprost longitudinal (c) n ϭ 3, radial (d) n ϭ 2; PGE 2 longitudinal (e) n ϭ 3, radial (f) n ϭ 2. 
